Novartis share falls after Phase III HARBOR del-desiran setback
Novartis AG (NVS) shares fell 12.40% premarket after the company said del-desiran failed its Phase III HARBOR study in myotonic dystrophy type 1, with no statistically significant improvement over placebo on hand opening time.
40% premarket after the Swiss drugmaker said del-desiran failed its Phase III HARBOR study in myotonic dystrophy type 1, with no statistically significant improvement versus placebo on hand opening time. It was the third setback in a week. Pelacarsen missed on cardiovasc…